News Releases

Date Title
07/25/2016 Summary ToggleEnanta Announces the U.S. Food and Drug Administration has approved AbbVie’s New, Once-Daily VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C Virus
07/18/2016 Summary ToggleEnanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 P.M. ET to Discuss Financial Results for Its Fiscal Third Quarter Ended June 30, 2016
06/20/2016 Summary ToggleEnanta Pharmaceuticals Initiates Proof-of-Concept Study with Pan-genotypic Cyclophilin Inhibitor EDP-494 in Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Virus
06/01/2016 Summary ToggleEnanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
05/09/2016 Summary ToggleEnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2016
04/27/2016 Summary ToggleEnanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Quarter Ended March 31, 2016
04/26/2016 Summary ToggleEnanta Pharmaceuticals to Present at the Deutsche Bank 41st Annual Healthcare Conference Presentation to be Webcast on May 4, 2016 at 8:00 A.M. ET
04/25/2016 Summary ToggleEnanta Announces U.S. FDA has Approved AbbVie’s Supplemental New Drug Application for Use of VIEKIRA PAK® without Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis
04/16/2016 Summary ToggleEnanta Announces New Data from AbbVie’s SURVEYOR-1 and SURVEYOR-2 Studies Showing High Sustained Virologic Response Rates after 8 or 12 Weeks of Treatment in Patients with any of Genotypes 1 through 6 of Hepatitis C Virus
04/15/2016 Summary ToggleEnanta Announces that AbbVie’s Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals